Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 27 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

30%

8 trials in Phase 3/4

Results Transparency

56%

10 of 18 completed with results

Key Signals

10 with results100% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (1)
Early P 1 (1)
P 1 (4)
P 2 (3)
P 3 (5)
P 4 (3)

Trial Status

Completed18
Unknown4
Recruiting3
Active Not Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06921720Not ApplicableRecruiting

Phosphorus-31 Spectroscopy in Phosphate Diabetes

NCT05181839CompletedPrimary

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

NCT03193476RecruitingPrimary

Registry for Patients With X-Linked Hypophosphatemia

NCT03651505Active Not RecruitingPrimary

X-linked Hypophosphatemia Disease Monitoring Program

NCT03748966Early Phase 1CompletedPrimary

Calcitriol Monotherapy for X-Linked Hypophosphatemia

NCT06525636Phase 1RecruitingPrimary

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT03745521Active Not RecruitingPrimary

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

NCT03775187UnknownPrimary

Expanded Access to Burosumab

NCT02915705Phase 3CompletedPrimary

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

NCT02537431Phase 3CompletedPrimary

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160Phase 3CompletedPrimary

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT01571596Phase 1CompletedPrimary

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

NCT01340482Phase 1CompletedPrimary

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

NCT00830674Phase 1CompletedPrimary

A Study of KRN23 in X-linked Hypophosphatemia

NCT02312687Phase 2CompletedPrimary

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

NCT02750618Phase 2CompletedPrimary

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

NCT02163577Phase 2CompletedPrimary

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

NCT04273490CompletedPrimary

Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls

NCT06067932CompletedPrimary

Foot Disorders in X-linked Hypophosphatemia

NCT04146935Phase 4CompletedPrimary

Examining the Effect of Burosumab on Muscle Function

Scroll to load more

Research Network

Activity Timeline